China Cognition and Aging Study

NCT ID: NCT03653156

Last Updated: 2024-04-19

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2000-01-01
• Study Completion Date: 2038-01-01

Brief Summary

The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:

1. To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data.

2. To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia.

3. To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia).

4. To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis.

5. To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models.

6. To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people.

7. To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients，which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up.

8. To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies.

9. To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia.

10. To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.

Detailed Description

This study involved participants including Mild cognitive impairment (MCI) and its subtypes、Sporadic Alzheimer's disease (SAD)、 Familial Alzheimer's disease (FAD)、Vascular dementia (VaD)、Normal control in community population and hospital population. Research contents are as follow:

1. Through the collection of basic demographic information and clinical data from the multi-center cohort, we will calculate the prevalence and incidence rate of AD, VaD, other dementia (mixed dementia, FTD, DLB, PDD, alcohol dementia, hydrocephalus dementia, post-traumatic dementia, etc.), and update the numbers every 1-2 years.

2. To clarify the conversion pattern from normal elderly to MCI and from MCI to dementia. Through the collection and analysis of current medical history, past history, family history, living habits, drug use, physical examination and other information, we will explore the protective and risk factors of dementia and its main subtypes (AD, VaD, Other dementia), including age, gender, education level, rural/urban, marital status, parental dementia history, dietary habbit, blood pressure, drinking, smoking, diabetes, hyperlipidemia, cerebrovascular disease, heart disease, depression, hearing impairment, exercise habits (Tai chi, etc.), dementia specialist influence on patients, occupation, BMI, lifestyle changes, air pollution, head injury , social contact, low-income, and other unknown protective or risk factors. To investigate the role of ApoE gene, especially ApoEε4 in the disease onset and development, and to explore the non-pharmacological interventions For the study purpose we do follow-up every 2or 3 years.

3. By using exome sequencing, GWAS, WGS and other methods, we will search for new mutations of known pathogenic genes (APP, PSEN1, PSEN2) of AD in China, find new pathogenic genes and susceptible genes of dementia and its main subtypes (AD and VaD), and understand their distribution. We will explore the independent and combined effect of susceptibility gene variation on the risk of illness in Chinese AD population, and to obtain the key mutation sites that have a clear relationship with the incidence of AD. We will do regular follow up visits for the FAD members with new mutations of pathogenic genes, and clarify the important role of new mutations of pathogenic genes during the onset and progression of AD.

4. We will collect the biofluids (blood, cerebrospinal fluid, urine, etc.) and 18F-FDG / 11C-PIB PET/MR multimodal imaging data from people with normal cognition, MCI, AD (sporadic and familial) and VaD, and conduct regular follow up. Discover and verify the SAD related susceptible gene and FAD related pathogenic gene mutation. Through analyzing the imaging data (such as MRI brain regional volume, 18F-FDG PET and cortical Aβ load), cerebrospinal fluid and plasma markers (such as Aβ, T-tau and P-tau) and clinical features (such as psychiatric symptoms and age of onset), we will develop gene chip with high sensitivity and high specificity for early screening of dementia; develop diagnostic kits for biofluid markers (blood and cerebrospinal fluid); determine imaging cut-off values at all stages of dementia in Chinese people. We will do correlation analysis to establish early diagnosis and risk prediction model for dementia, and verify the newly developed instruments that can detect the peripheral markers of dementia patients and predict the disease progression in national large sample.

5. Through the unified and standardized neuropsychological scales, including MMSE, MoCA, CDR, NPI, ADL, etc, we will conduct investigation to subjects in baseline and follow-up period, and analyze the changes of cognitive function, ability of daily life and mental behavior symptoms in different cognitive disorders. According to the social, cultural and material changes in China in recent years, we will develop psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people. Meanwhile, on the basis of the international diagnostic standards of various subtypes of dementia, combined with the etiology, clinical manifestations, scale classification, imaging characteristics, biofluid examination, etc., we will study the novel typing method and diagnostic standards of cognitive normal, MCI, dementia and its subtypes (clinical and molecular subtypes) in Chinese population.

6. Through designing randomized controlled trials, we will study the systematic and effective NPT intervention program, including lifestyle (diet and sleep habits, smoking, drinking and social networking), health products, exercise habits, cognitive training, risk factor control, etc. We will explore the quantitative and objective evaluation criteria of NPT in AD and dementia, clarify its prevention and control efficacy on APOE ε4 carriers, MCI and dementia patients, and potential neurobiological mechanism. At the same time, we will carry out dementia related education in the community, improve the public knowledge, attention and awareness of dementia, so that patients can get early detection, early diagnosis and early intervention.

7. To explore the relationship between dementia as well as its major subtype AD and cerebral circulatory disorders (cerebral ischemic and hemorrhage diseases, cerebral arteriosclerosis and stenosis, cerebral venous diseases, etc.), especially clarify the relationship between chronic cerebral ischemia and AD, as well as its effect on AD onset, and whether or not it's risk factor for AD. Whether the therapeutic strategies for cerebral circulatory disorders should be included in the treatment of AD.

Conditions

Mild Cognitive Impairment(MCI); Alzheimer Disease, Late Onset; Familial Alzheimer Disease (FAD); Vascular Dementia (VaD); Normal Control; Non-Alzheimer Degenerative Dementia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Mild cognitive impairment (MCI) and its subtypes

MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.

No interventions assigned to this group

Sporadic Alzheimer's disease (SAD)

SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.

No interventions assigned to this group

Familial Alzheimer's disease (FAD)

FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.

No interventions assigned to this group

Vascular dementia(VaD）

VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.

No interventions assigned to this group

Normal control

Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.

No interventions assigned to this group

Non-Alzheimer degenerative dementia

Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Diagnosis according to 2004 Peterson's MCI criteria.

2. CDR = 0.5.

3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.

4. Insidious onset, slow progress.

5. Not reaching the level of dementia.

1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.

2. Subjects and their informed persons can complete relevant and follow- up examinations.

3. Subjects or their authorized legal guardians sign the informed consent.

1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.

2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).

3. Aged 18 (inclusive) or older.

4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.

Diagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.

1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.

2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).

3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).

1. Aged 18 (inclusive) or above.

2. Normal MMSE and MoCA evaluations. MMSE>19 points for illiteracy, >24 points for those educated less than 7 years, >27 points for those educated equal to or more than 7 years. MoCA>13 points for illiteracy, >19 points for those educated less than 7 years, >24 points for those educated equal to or more than 7 years.

Exclusion Criteria

1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).

2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

4. Mental and neurodevelopmental retardation.

5. Contraindications to MRI.

6. Suffering from a disease that cannot be combined with cognitive examination.

7. Refuse to draw blood.

8. Refuse to sign the informed consent at baseline

(2) Sporadic Alzheimer's disease (SAD)

1. With a family history of dementia.

2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

4. Mental and neurodevelopmental retardation.

5. Contraindications to MRI.

6. Suffering from a disease that cannot be combined with cognitive examination.

7. Refuse to draw blood.

8. Refuse to sign the informed consent at baseline

(3) Familial Alzheimer's disease (FAD)

1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).

2. MRI and laboratory tests do not support or rule out a diagnosis of AD.

3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.

4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.

5. With history of alcohol or drug abuse.

6. Pregnant or lactating women.

7. No reliable insiders.

8. Refuse to sign the informed consent at baseline.

(4) Vascular dementia (VaD)

1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

3. With a history of mental illness or those with congenital mental retardation.

4. Suffering from a disease that cannot be combined with a cognitive examination.

5. Contraindications to MRI.

6. Refuse to draw blood.

7. Refuse to sign informed consent.

(5) Normal control

1. Subjects with abnormal MMSE or MoCA scores.

2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.

3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

5. Mental and neurodevelopmental retardation.

6. Suffering from a disease that cannot be combined with a cognitive examination.

7. Contraindications to MRI.

8. Refuse to draw blood.

9. Refuse to sign the informed consent at baseline.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Beijing Tiantan Hospital

OTHER

Sponsor Role: collaborator

Beijing Chao Yang Hospital

OTHER

Sponsor Role: collaborator

Fu Xing Hospital, Capital Medical University

OTHER

Sponsor Role: collaborator

Peking Union Medical College Hospital

OTHER

Sponsor Role: collaborator

Peking University First Hospital

OTHER

Sponsor Role: collaborator

Peking University Third Hospital

OTHER

Sponsor Role: collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role: collaborator

China-Japan Friendship Hospital

OTHER

Sponsor Role: collaborator

Beijing Geriatric Hospital

OTHER

Sponsor Role: collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

Sponsor Role: collaborator

Fujian Medical University Union Hospital

OTHER

Sponsor Role: collaborator

Guangzhou Psychiatric Hospital

OTHER_GOV

Sponsor Role: collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

Sponsor Role: collaborator

The Affiliated Hospital Of Guizhou Medical University

OTHER

Sponsor Role: collaborator

Handan Central Hospital

OTHER

Sponsor Role: collaborator

Hebei General Hospital

OTHER

Sponsor Role: collaborator

First Hospital of Shijiazhuang City

OTHER

Sponsor Role: collaborator

Tangshan Worker's Hospital

OTHER

Sponsor Role: collaborator

Hunan Provincial People's Hospital

OTHER

Sponsor Role: collaborator

Kaifeng Central Hospital

OTHER

Sponsor Role: collaborator

People's Hospital of Zhengzhou University

OTHER

Sponsor Role: collaborator

Zhongnan Hospital

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Harbin Medical University

OTHER

Sponsor Role: collaborator

Tongji Hospital

OTHER

Sponsor Role: collaborator

People's Hospital Affiliated Hubei Medical University

UNKNOWN

Sponsor Role: collaborator

The Third Xiangya Hospital of Central South University

OTHER

Sponsor Role: collaborator

Xiangya Hospital of Central South University

OTHER

Sponsor Role: collaborator

The First Hospital of Jilin University

OTHER

Sponsor Role: collaborator

China-Japan Union Hospital, Jilin University

OTHER

Sponsor Role: collaborator

Subei People's Hospital of Jiangsu

UNKNOWN

Sponsor Role: collaborator

Nantong University Affiliated Hospital

UNKNOWN

Sponsor Role: collaborator

Mineral General Hospital, Xuzhou

UNKNOWN

Sponsor Role: collaborator

Jiangxi Provincial People's Hopital

OTHER

Sponsor Role: collaborator

Anshan Central Hospital

OTHER

Sponsor Role: collaborator

Affiliated Zhongshan Hospital of Dalian University

OTHER

Sponsor Role: collaborator

First Hospital of China Medical University

OTHER

Sponsor Role: collaborator

Baotou Central Hospital

OTHER

Sponsor Role: collaborator

General Hospital of Ningxia Medical University

OTHER

Sponsor Role: collaborator

The People's Hospital of Ningxia

OTHER

Sponsor Role: collaborator

The Affiliated Hospital of Qingdao University

OTHER

Sponsor Role: collaborator

The 960th Hospital of PLA

UNKNOWN

Sponsor Role: collaborator

Qilu Hospital of Shandong University

OTHER

Sponsor Role: collaborator

Qilu Hospital of Shandong University (Qingdao)

OTHER

Sponsor Role: collaborator

Shandong Provincial Hospital

OTHER_GOV

Sponsor Role: collaborator

Qingdao Municipal Hospital

OTHER

Sponsor Role: collaborator

The First Affiliated Hospital of Shanxi Medical University

OTHER

Sponsor Role: collaborator

Tang-Du Hospital

OTHER

Sponsor Role: collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role: collaborator

Ruijin Hospital

OTHER

Sponsor Role: collaborator

RenJi Hospital

OTHER

Sponsor Role: collaborator

Shanghai Changzheng Hospital

OTHER

Sponsor Role: collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

Sponsor Role: collaborator

Tianjin Huanhu Hospital

OTHER

Sponsor Role: collaborator

Tianjin Medical University General Hospital

OTHER

Sponsor Role: collaborator

Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region

UNKNOWN

Sponsor Role: collaborator

Ningbo Medical Center Lihuili Hospital

OTHER_GOV

Sponsor Role: collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Zhejiang University

OTHER

Sponsor Role: collaborator

Shao Yifu Hospital of Zhejiang Medical University

UNKNOWN

Sponsor Role: collaborator

Zhejiang Provincial People's Hospital

OTHER

Sponsor Role: collaborator

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

Sponsor Role: collaborator

The Second Affiliated Hospital of Chongqing Medical University

OTHER

Sponsor Role: collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

Sponsor Role: collaborator

People's Hospital of Chongqing

OTHER

Sponsor Role: collaborator

Dongfang Hospital Beijing University of Chinese Medicine

OTHER

Sponsor Role: collaborator

Zigong No.1 Peoples Hospital

OTHER

Sponsor Role: collaborator

Capital Medical University

OTHER

Sponsor Role: lead

Responsible Party

Jianping Jia

Chief Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jianping Jia, Doctor

Role: STUDY_CHAIR

Xuanwu Hospital of Capital Medical University

Locations

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Site Status: RECRUITING

Beijing Geriatric Hospital

Changping, Beijing Municipality, China

Site Status: RECRUITING

Beijing Chao Yang Hospital

Chaoyang, Beijing Municipality, China

Site Status: RECRUITING

China-Japan Friendship Hospital

Chaoyang, Beijing Municipality, China

Site Status: RECRUITING

Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

Fengtai, Beijing Municipality, China

Site Status: RECRUITING

Chinese PLA General Hospital

Haidian, Beijing Municipality, China

Site Status: RECRUITING

Fu Xing Hospital, Capital Medical University

Haidian, Beijing Municipality, China

Site Status: RECRUITING

Peking University Third Hospital

Haidian, Beijing Municipality, China

Site Status: RECRUITING

Peking Union Medical College Hospital

Xicheng, Beijing Municipality, China

Site Status: RECRUITING

Peking University First Hospital

Xicheng, Beijing Municipality, China

Site Status: RECRUITING

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Yuzhong, Chongqing Municipality, China

Site Status: RECRUITING

The Second Affiliated Hospital of Chongqing Medical University

Yuzhong, Chongqing Municipality, China

Site Status: RECRUITING

Fujian Medical University Union Hospital

Fujian, Guangdong, China

Site Status: RECRUITING

Guangzhou Psychiatric Hospital

Guangzhou, Guangdong, China

Site Status: RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Zhongshan, Guangdong, China

Site Status: RECRUITING

First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Site Status: RECRUITING

The Affiliated Hospital Of Guizhou Medical University

Guiyang, Guizhou, China

Site Status: RECRUITING

Handan Central Hospital

Handan, Hebei, China

Site Status: RECRUITING

First Hospital of Shijiazhuang City

Shijiazhuang, Hebei, China

Site Status: RECRUITING

Tangshan Worker's Hospital

Tangshan, Hebei, China

Site Status: RECRUITING

Hebei General Hospital

Zhijiazhuang, Hebei, China

Site Status: RECRUITING

First Affiliated Hospital of Harbin Medical University

Haerbin, Heilongjiang, China

Site Status: RECRUITING

Kaifeng Central Hospital

Kaifeng, Henan, China

Site Status: RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Site Status: RECRUITING

People's Hospital of Zhengzhou

Zhengzhou, Henan, China

Site Status: RECRUITING

People's Hospital Affiliated Hubei Medical University

Wuhan, Hubei, China

Site Status: RECRUITING

Tongji Hospital

Wuhan, Hubei, China

Site Status: RECRUITING

The Third Xiangya Hospital of Central South University

Wuhan, Hunan, China

Site Status: RECRUITING

Wuhan University Zhongnan Hospital

Wuhan, Hunan, China

Site Status: RECRUITING

Xiangya Hospital of Central South University

Wuhan, Hunan, China

Site Status: RECRUITING

Nantong University Affiliated Hospital

Nantong, Jiangsu, China

Site Status: RECRUITING

Subei People's Hospital of Jiangsu

Subei, Jiangsu, China

Site Status: RECRUITING

Mineral General Hospital, Xuzhou

Xuzhou, Jiangsu, China

Site Status: RECRUITING

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Site Status: RECRUITING

China-Japan friendship Hospital of Jilin university

Changchun, Jilin, China

Site Status: RECRUITING

The First Hospital of Jilin University

Changchun, Jilin, China

Site Status: RECRUITING

Changda Hospital, Anshan

Anshan, Liaoning, China

Site Status: RECRUITING

Affiliated Zhongshan hospital of Dalian university

Dalian, Liaoning, China

Site Status: RECRUITING

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

Site Status: RECRUITING

First Hospital of China Medical University

Shenyang, Liaoning, China

Site Status: RECRUITING

Baotou Central Hospital

Baotou, Nei Monggol, China

Site Status: RECRUITING

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Site Status: RECRUITING

The People's Hospital of Ningxia

Yinchuan, Ningxia, China

Site Status: RECRUITING

Qilu Hospital of Shandong University

Jinan, Shandong, China

Site Status: RECRUITING

Shandong Provincial Hospital

Jining, Shandong, China

Site Status: RECRUITING

Qilu Hospital of Shandong University (Qingdao)

Qingdao, Shandong, China

Site Status: RECRUITING

QingDao Municipal Hospital

Qingdao, Shandong, China

Site Status: RECRUITING

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Site Status: RECRUITING

The 88th Hospital of PLA

Tai’an, Shandong, China

Site Status: RECRUITING

Shanghai Changzheng Hospital

Huangpu, Shanghai Municipality, China

Site Status: RECRUITING

Ruijin Hospital

Luwan, Shanghai Municipality, China

Site Status: RECRUITING

RenJi Hospital

Putong, Shanghai Municipality, China

Site Status: RECRUITING

The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Site Status: RECRUITING

First Affiliated Hospital Xi'an Jiaotong University

Xi’an, Shanxi, China

Site Status: RECRUITING

Tang-Du Hospital

Xi’an, Shanxi, China

Site Status: RECRUITING

Affiliated Hospital of North Sichuan Medical College

Nanchong, Sichuan, China

Site Status: RECRUITING

Zigong First People's Hospital

Zigong, Sichuan, China

Site Status: RECRUITING

Tianjin Huanhu Hospital

Xianshuigu, Tianjin Municipality, China

Site Status: RECRUITING

Tianjin Medical University General Hospital

Xiaobailou, Tianjin Municipality, China

Site Status: RECRUITING

Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region

Ürümqi, Xinjiang, China

Site Status: RECRUITING

First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Shao Yifu Hospital of Zhejiang Medical University

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Ningbo City Medical Treatment Center Lihuili Hospital

Ningbo, Zhejiang, China

Site Status: RECRUITING

First Affiliated Hospital of Wenzhou Medical Univeristy

Wenzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jianping Jia, Doctor

Role: CONTACT

jiajp@vip.126.com

Facility Contacts

Yanghua Tian, Doctor

Role: primary

ayfytyh@126.com

Jihui Lv

Role: primary

lvjihui@139.com

Yue Wang, Doctor

Role: primary

wyjoe2000@163.com

Dantao Peng

Role: primary

pengdantao@medmail.com.cn

Lanxiang Jin, Doctor

Role: primary

jxlan2001@126.com

Jianjun Jia, Doctor

Role: primary

jiajianjun301@126.com

Fang Li, Doctor

Role: primary

lifangwa@sina.com

Weizhong Xiao

Role: primary

weizhongx@sina.com

Jing Gao, Doctor

Role: primary

gj107@163.com

Zhirong Jia

Role: primary

jiazhirong@163.com

Yanjiang Wang

Role: primary

Yingying Shen

Role: backup

123473534@qq.com

Yangmei Chen

Role: primary

chenym1997@tom.com

Qinyong Ye

Role: primary

unionqyye@163.com

Mouni Tang, Doctor

Role: primary

munitang@163.com

Jun Liu, Doctor

Role: primary

docliujun@126.com

Shengliang Liang

Role: primary

ssl_1964@163.com

Lan Chu, Doctor

Role: primary

chulan8999@sohu.com

Minchen Kan, Doctor

Role: primary

623090112@qq.com

Huiying Zhao

Role: primary

13323119938@163.com

Yongqiu Li, Doctor

Role: primary

yongqiuli@126.com

Peiyuan Lv, Doctor

Role: primary

peiyuanlu@163.com

Shurong Duan, Doctor

Role: primary

duanshurongsj@163.com

Huanrong Yu, Doctor

Role: primary

yrh0656@126.com

Jiewen Zhang, Doctor

Role: primary

zhangjiewen9900@126.com

Shuling Zhang, Doctor

Role: primary

Bin Zhang

Role: backup

Zyuanyuan1121@163.com

Jianjun Zhang, Doctor

Role: primary

xsssm@sina.cn

Min Zhang

Role: primary

4082410998@qq.com

Lu Shen

Role: primary

shenlu2505@126.com

Hanxing Liu

Role: primary

hanxing_liu@whu.Ed.cn

Qiuyun Tu, Doctor

Role: primary

qiuyuntu@126.com

Maohong Cao, Doctor

Role: primary

yty5532917@163.com

Jun Xu, Doctor

Role: primary

13611572068@126.com

Liangqun Rong, Doctor

Role: primary

rongliangqun@163.com

Kunnan Zhang, Doctor

Role: primary

zkn8@163.com

Qin Zhao, Doctor

Role: primary

1292860277@qq.com

Li Sun, Doctor

Role: primary

sjnksunli@163.com

Xiu Han, Doctor

Role: primary

ashanxj@163.com

Qiang Ma, Doctor

Role: primary

13332258950@163.com

Cui Wang, Doctor

Role: primary

wangc817@163.com

Yunpeng Cao, Doctor

Role: primary

cypcmu@163.com

Furu Liang, Doctor

Role: primary

ru_liang@sina.com

Qin Zhang, Doctor

Role: primary

nxzhangqing@aliyun.com

Yongying Gao, Doctor

Role: primary

18169110878@163.com

Peiyan Shan, Doctor

Role: primary

Shanpy57@163.com

Yifeng Du, Doctor

Role: primary

duyifeng2013@163.com

Bin Liang, Doctor

Role: primary

bingliangbin@163.com

Lan Tan, Doctor

Role: primary

dr.tanlan@163.com

Jinping Sun, Doctor

Role: primary

sunjinping@sina.com

Jintao Zhang, Doctor

Role: primary

zjtdoctor@126.com

Jianhua Zhuang, Doctor

Role: primary

jianhuazh11@126.com

Gang Wang, Doctor

Role: primary

wgneuron@hotmail.com

Qun Xu, Doctor

Role: primary

xuqun628@163.com

Yuling Tian, Doctor

Role: primary

tylzcy2018@163.com

Qiumin Qu, Doctor

Role: primary

quqiumin@medmail.com.cn

Wei Zhang, Doctor

Role: primary

zw711711@hotmail.com

Ying Ma, Doctor

Role: primary

yingma1314@126.com

Xiaoya Xu, Doctor

Role: primary

502687651@qq.com

Yuying Zhou, Doctor

Role: primary

Qiying789@sina.cn

Nan Zhang, Doctor

Role: primary

nkzhangnan@163.com

Xinling Meng

Role: primary

altmxl@126.com

Benyan Luo, Doctor

Role: primary

luobenyan@zju.edu.cn

Peilin Lu, Doctor

Role: primary

lplzxa@163.com

Enyan Yu

Role: primary

yuenyan@aliyun.com

Guomin Xie, Doctor

Role: primary

drxie01@qq.com

Zhen Wang

Role: primary

Jane.wz@163.com

References

Zhou A, Jia J. A screen for cognitive assessments for patients with vascular cognitive impairment no dementia. Int J Geriatr Psychiatry. 2009 Dec;24(12):1352-7. doi: 10.1002/gps.2265.

Reference Type: RESULT

PMID: 19347838 (View on PubMed)

Zhou A, Jia J. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. J Int Neuropsychol Soc. 2009 Nov;15(6):898-905. doi: 10.1017/S1355617709990816.

Reference Type: RESULT

PMID: 19891819 (View on PubMed)

Bai F, Liao W, Watson DR, Shi Y, Yuan Y, Cohen AD, Xie C, Wang Y, Yue C, Teng Y, Wu D, Jia J, Zhang Z. Mapping the altered patterns of cerebellar resting-state function in longitudinal amnestic mild cognitive impairment patients. J Alzheimers Dis. 2011;23(1):87-99. doi: 10.3233/JAD-2010-101533.

Reference Type: RESULT

PMID: 20930266 (View on PubMed)

Han Y, Wang J, Zhao Z, Min B, Lu J, Li K, He Y, Jia J. Frequency-dependent changes in the amplitude of low-frequency fluctuations in amnestic mild cognitive impairment: a resting-state fMRI study. Neuroimage. 2011 Mar 1;55(1):287-95. doi: 10.1016/j.neuroimage.2010.11.059. Epub 2010 Nov 28.

Reference Type: RESULT

PMID: 21118724 (View on PubMed)

Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, Jia XF, Song H, Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol. 2011 Dec;24(4):184-90. doi: 10.1177/0891988711422528.

Reference Type: RESULT

PMID: 22228824 (View on PubMed)

Shi FD, Jia JP. Neurology and neurologic practice in China. Neurology. 2011 Nov 29;77(22):1986-92. doi: 10.1212/WNL.0b013e31823a0ed3.

Reference Type: RESULT

PMID: 22123780 (View on PubMed)

Han Y, Jia J, Jia XF, Qin W, Wang S. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease. Neurosci Lett. 2012 May 16;516(2):232-6. doi: 10.1016/j.neulet.2012.03.094. Epub 2012 Apr 7.

Reference Type: RESULT

PMID: 22503901 (View on PubMed)

Li F, Jia XF, Jia J. The Informant Questionnaire on Cognitive Decline in the Elderly individuals in screening mild cognitive impairment with or without functional impairment. J Geriatr Psychiatry Neurol. 2012 Dec;25(4):227-32. doi: 10.1177/0891988712464822. Epub 2012 Nov 21.

Reference Type: RESULT

PMID: 23172761 (View on PubMed)

Song J, Wang S, Tan M, Jia J. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. Neurosci Lett. 2012 Sep 27;526(2):144-9. doi: 10.1016/j.neulet.2012.08.020. Epub 2012 Aug 17.

Reference Type: RESULT

PMID: 22922216 (View on PubMed)

Tan M, Wang S, Song J, Jia J. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neurosci Lett. 2012 May 16;516(2):226-31. doi: 10.1016/j.neulet.2012.03.093. Epub 2012 Apr 6.

Reference Type: RESULT

PMID: 22503900 (View on PubMed)

Wang F, Shu C, Jia L, Zuo X, Zhang Y, Zhou A, Qin W, Song H, Wei C, Zhang F, Hong Z, Tang M, Wang DM, Jia J. Exploration of 16 candidate genes identifies the association of IDE with Alzheimer's disease in Han Chinese. Neurobiol Aging. 2012 May;33(5):1014.e1-9. doi: 10.1016/j.neurobiolaging.2010.08.004. Epub 2010 Sep 28.

Reference Type: RESULT

PMID: 20880607 (View on PubMed)

Wang S, Song J, Tan M, Albers KM, Jia J. Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease. Eur J Neurol. 2012 Jul;19(7):1015-22. doi: 10.1111/j.1468-1331.2012.03670.x. Epub 2012 Feb 16.

Reference Type: RESULT

PMID: 22340708 (View on PubMed)

Xing Y, Qin W, Li F, Jia XF, Jia J. Apolipoprotein E epsilon4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33(1):35-42. doi: 10.1159/000336600. Epub 2012 Mar 2.

Reference Type: RESULT

PMID: 22398564 (View on PubMed)

Xing Y, Wei C, Chu C, Zhou A, Li F, Wu L, Song H, Zuo X, Wang F, Qin W, Li D, Tang Y, Jia XF, Jia J. Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia. Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):433-8. doi: 10.1177/1533317512454712.

Reference Type: RESULT

PMID: 22930700 (View on PubMed)

Li F, Wang F, Jia J. Evaluating the prevalence of dementia in hospitalized older adults and effects of comorbid dementia on patients' hospital course. Aging Clin Exp Res. 2013 Aug;25(4):393-401. doi: 10.1007/s40520-013-0068-z. Epub 2013 Jul 20.

Reference Type: RESULT

PMID: 23872925 (View on PubMed)

Xing Y, Qin W, Li F, Jia XF, Jia J. Associations between sex hormones and cognitive and neuropsychiatric manifestations in vascular dementia (VaD). Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):85-90. doi: 10.1016/j.archger.2012.10.003. Epub 2012 Oct 24.

Reference Type: RESULT

PMID: 23103091 (View on PubMed)

Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014 Jan;10(1):1-9. doi: 10.1016/j.jalz.2013.01.012. Epub 2013 Jul 18.

Reference Type: RESULT

PMID: 23871765 (View on PubMed)

Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X, Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. Alzheimers Dement. 2014 Jul;10(4):439-447. doi: 10.1016/j.jalz.2013.09.008. Epub 2014 Jan 10.

Reference Type: RESULT

PMID: 24418053 (View on PubMed)

Qin W, Jia X, Wang F, Zuo X, Wu L, Zhou A, Li D, Min B, Wei C, Tang Y, Xing Y, Dong X, Wang Q, Gao Y, Li Y, Jia J. Elevated plasma angiogenesis factors in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):245-52. doi: 10.3233/JAD-142409.

Reference Type: RESULT

PMID: 25690662 (View on PubMed)

Song H, Long H, Zuo X, Yu C, Liu B, Wang Z, Wang Q, Wang F, Han Y, Jia J. APOE Effects on Default Mode Network in Chinese Cognitive Normal Elderly: Relationship with Clinical Cognitive Performance. PLoS One. 2015 Jul 15;10(7):e0133179. doi: 10.1371/journal.pone.0133179. eCollection 2015.

Reference Type: RESULT

PMID: 26177270 (View on PubMed)

Jia J, Zuo X, Jia XF, Chu C, Wu L, Zhou A, Wei C, Tang Y, Li D, Qin W, Song H, Ma Q, Li J, Sun Y, Min B, Xue S, Xu E, Yuan Q, Wang M, Huang X, Fan C, Liu J, Ren Y, Jia Q, Wang Q, Jiao L, Xing Y, Wu X; China Cognition and Aging Study (China COAST) Group. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. Alzheimers Dement. 2016 Apr;12(4):446-53. doi: 10.1016/j.jalz.2015.06.1892. Epub 2015 Aug 7.

Reference Type: RESULT

PMID: 26256457 (View on PubMed)

Li H, Jia J, Yang Z. Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study. J Alzheimers Dis. 2016 May 7;53(2):487-96. doi: 10.3233/JAD-160119.

Reference Type: RESULT

PMID: 27163822 (View on PubMed)

Xing Y, Tang Y, Zhao L, Wang Q, Qin W, Zhang JL, Jia J. Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1029-35. doi: 10.3233/JAD-151158.

Reference Type: RESULT

PMID: 27079712 (View on PubMed)

Yuan X, Han Y, Wei Y, Xia M, Sheng C, Jia J, He Y. Regional homogeneity changes in amnestic mild cognitive impairment patients. Neurosci Lett. 2016 Aug 26;629:1-8. doi: 10.1016/j.neulet.2016.06.047. Epub 2016 Jun 23.

Reference Type: RESULT

PMID: 27345927 (View on PubMed)

Li D, Hu N, Yu Y, Zhou A, Li F, Jia J. Trajectories of Multidimensional Caregiver Burden in Chinese Informal Caregivers for Dementia: Evidence from Exploratory and Confirmatory Factor Analysis of the Zarit Burden Interview. J Alzheimers Dis. 2017;59(4):1317-1325. doi: 10.3233/JAD-170172.

Reference Type: RESULT

PMID: 28759966 (View on PubMed)

Liu Q, Zhu Z, Teipel SJ, Yang J, Xing Y, Tang Y, Jia J. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front Aging Neurosci. 2017 Feb 27;9:47. doi: 10.3389/fnagi.2017.00047. eCollection 2017.

Reference Type: RESULT

PMID: 28289381 (View on PubMed)

Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9.

Reference Type: RESULT

PMID: 29433981 (View on PubMed)

Li J, Wu L, Tang Y, Zhou A, Wang F, Xing Y, Jia J. Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. BMC Neurol. 2018 May 10;18(1):65. doi: 10.1186/s12883-018-1068-6.

Reference Type: RESULT

PMID: 29747584 (View on PubMed)

Qiu Q, Shen L, Jia L, Wang Q, Li F, Li Y, Jia J. A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Abeta42/Abeta40 ratio. J Alzheimers Dis. 2019;69(1):199-212. doi: 10.3233/JAD-181291.

Reference Type: RESULT

PMID: 30958370 (View on PubMed)

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019 Aug;15(8):1071-1080. doi: 10.1016/j.jalz.2019.05.002.

Reference Type: RESULT

PMID: 31422798 (View on PubMed)

Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, Wang Q, Yan X, Kong C, Hao J, Wei C, Tang Y, Qin W, Li Y, Wang F, Guo D, Zhou A, Zuo X, Yu Y, Li D, Zhao L, Jin H, Jia J. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease. Alzheimers Dement. 2020 Jan;16(1):178-191. doi: 10.1002/alz.12005.

Reference Type: RESULT

PMID: 31914229 (View on PubMed)

Zhao T, Quan M, Jia J. Functional Connectivity of Default Mode Network Subsystems in the Presymptomatic Stage of Autosomal Dominant Alzheimer's Disease. J Alzheimers Dis. 2020;73(4):1435-1444. doi: 10.3233/JAD-191065.

Reference Type: RESULT

PMID: 31929167 (View on PubMed)

Quan M, Zhao T, Tang Y, Luo P, Wang W, Qin Q, Li T, Wang Q, Fang J, Jia J. Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer's disease. Alzheimers Res Ther. 2020 Jan 14;12(1):14. doi: 10.1186/s13195-019-0572-2.

Reference Type: RESULT

PMID: 31937364 (View on PubMed)

Jia L, Xu H, Chen S, Wang X, Yang J, Gong M, Wei C, Tang Y, Qu Q, Chu L, Shen L, Zhou C, Wang Q, Zhao T, Zhou A, Li Y, Li F, Li Y, Jin H, Qin Q, Jiao H, Li Y, Zhang H, Lyu D, Shi Y, Song Y, Jia J. The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease. Alzheimers Dement. 2020 Dec;16(12):1613-1623. doi: 10.1002/alz.12153. Epub 2020 Sep 3.

Reference Type: RESULT

PMID: 32881347 (View on PubMed)

Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, Wei C, Tang Y, Wang Q, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia J. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. Alzheimers Dement. 2021 Jan;17(1):49-60. doi: 10.1002/alz.12166. Epub 2020 Aug 10.

Reference Type: RESULT

PMID: 32776690 (View on PubMed)

Han Y, Zhou A, Li F, Wang Q, Xu L, Jia J. Apolipoprotein E epsilon4 allele is associated with vascular cognitive impairment no dementia in Chinese population. J Neurol Sci. 2020 Feb 15;409:116606. doi: 10.1016/j.jns.2019.116606. Epub 2019 Dec 6.

Reference Type: RESULT

PMID: 31865187 (View on PubMed)

Qiu Q, Jia L, Wang Q, Zhao L, Jin H, Li T, Quan M, Xu L, Li B, Li Y, Jia J. Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease. Neurobiol Aging. 2020 Jan;85:155.e1-155.e4. doi: 10.1016/j.neurobiolaging.2019.05.018. Epub 2019 May 31.

Reference Type: RESULT

PMID: 31235344 (View on PubMed)

Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M, Jiao H, Song Y, Shi Y, Zhang H, Gong M, Wei C, Tang Y, Fang B, Guo D, Wang F, Zhou A, Chu C, Zuo X, Yu Y, Yuan Q, Wang W, Li F, Shi S, Yang H, Zhou C, Liao Z, Lv Y, Li Y, Kan M, Zhao H, Wang S, Yang S, Li H, Liu Z, Wang Q, Qin W, Jia J; COAST Group. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020 Dec;5(12):e661-e671. doi: 10.1016/S2468-2667(20)30185-7.

Reference Type: RESULT

PMID: 33271079 (View on PubMed)

Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y, Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, Zhang J, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y, Liang J, Wang Q, Jin H, Wang W, Lu Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, Li Y, Kong C, Li Y, Jiao H, Lu J, Jia J. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain. 2021 Apr 12;144(3):924-937. doi: 10.1093/brain/awaa364.

Reference Type: RESULT

PMID: 33188687 (View on PubMed)

Qin W, Zhou A, Zuo X, Jia L, Li F, Wang Q, Li Y, Wei Y, Jin H, Cruchaga C, Benitez BA, Jia J. Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease. Hum Mol Genet. 2021 May 28;30(9):811-822. doi: 10.1093/hmg/ddab090.

Reference Type: RESULT

PMID: 33835157 (View on PubMed)

Jia J, Zhao T, Liu Z, Liang Y, Li F, Li Y, Liu W, Li F, Shi S, Zhou C, Yang H, Liao Z, Li Y, Zhao H, Zhang J, Zhang K, Kan M, Yang S, Li H, Liu Z, Ma R, Lv J, Wang Y, Yan X, Liang F, Yuan X, Zhang J, Gauthier S, Cummings J. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ. 2023 Jan 25;380:e072691. doi: 10.1136/bmj-2022-072691.

Reference Type: RESULT

PMID: 36696990 (View on PubMed)

Jia J, Zhang Y, Shi Y, Yin X, Wang S, Li Y, Zhao T, Liu W, Zhou A, Jia L. A 19-Year-Old Adolescent with Probable Alzheimer's Disease. J Alzheimers Dis. 2023;91(3):915-922. doi: 10.3233/JAD-221065.

Reference Type: RESULT

PMID: 36565128 (View on PubMed)

Li W, Pang Y, Wang Y, Mei F, Guo M, Wei Y, Li X, Qin W, Wang W, Jia L, Jia J. Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer's disease. BMC Med. 2023 Jun 26;21(1):223. doi: 10.1186/s12916-023-02930-7.

Reference Type: RESULT

PMID: 37365538 (View on PubMed)

Quan M, Wang Q, Qin W, Wang W, Li F, Zhao T, Li T, Qiu Q, Cao S, Wang S, Wang Y, Jin H, Zhou A, Fang J, Jia L, Jia J. Shared and unique effects of ApoEepsilon4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimers Res Ther. 2023 Feb 28;15(1):40. doi: 10.1186/s13195-023-01192-y.

Reference Type: RESULT

PMID: 36850008 (View on PubMed)

Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, Ding J, Li Y, Zhao B, Lyu J, Yang S, Yan X, Wang Y, Qin W, Wang Q, Li Y, Zhang J, Liang F, Liao Z, Wang S. Biomarker Changes during 20 Years Preceding Alzheimer's Disease. N Engl J Med. 2024 Feb 22;390(8):712-722. doi: 10.1056/NEJMoa2310168.

Reference Type: RESULT

PMID: 38381674 (View on PubMed)

Zhao B, Zang P, Quan M, Wang Q, Guo D, Jia J, Wang W. The Effect of APOE epsilon4 on Alzheimer's Disease Fluid Biomarkers: A Cross-Sectional Study Based on the COAST. CNS Neurosci Ther. 2025 Jan;31(1):e70202. doi: 10.1111/cns.70202.

Reference Type: DERIVED

PMID: 39749650 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Related Links

http://ad.chinacfan.org/Default.aspx

COAST Website

Other Identifiers

SYXWJ001

Identifier Type: -

Identifier Source: org_study_id